Scientific opinion on the relationship between intake of alpha-lipoic acid (thioctic acid) and the risk of insulin autoimmune syndrome.
Hirata's disease
Thioctic acid
case report
comprehensive literature search
food supplement
genetic determinants
insulin autoimmune syndrome
Journal
EFSA journal. European Food Safety Authority
ISSN: 1831-4732
Titre abrégé: EFSA J
Pays: United States
ID NLM: 101642076
Informations de publication
Date de publication:
Jun 2021
Jun 2021
Historique:
entrez:
14
6
2021
pubmed:
15
6
2021
medline:
15
6
2021
Statut:
epublish
Résumé
Following a request from the European Commission, the EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) was asked to deliver an opinion on the relationship between alpha-lipoic acid (ALA) and the risk of insulin autoimmune syndrome (IAS). The Panel was also asked to advise on the dose below which ALA added to foods is not expected to cause IAS. A review of all possible adverse effects associated with consumption of ALA was not requested. This mandate refers to the procedure under Article 8(2) of Regulation (EC) No 1925/2006 on addition of vitamins, minerals and certain other substances to foods. No pre-established rule exists for the evaluation of the safety of foods when classical toxicity tests cannot be used, e.g. for autoimmune diseases. Published scientific evidence was retrieved through comprehensive literature searches, particularly 49 case reports in which IAS developed following ALA consumption. In all cases, IAS resolved after a few weeks to months when ALA was discontinued. No publication linking the intake of ALA naturally occurring in foods to IAS was identified. The Panel concludes that the consumption of ALA added to foods, including food supplements, is likely to increase the risk of developing IAS in individuals with certain genetic polymorphisms, who cannot be readily identified without genetic testing. The plausible mechanism of such an effect has not yet been fully elucidated. The incidence of IAS in Europe is low and likely lower than in Japan where it has been estimated to be 0.017 per 100,000 inhabitants in 2017-2018. Considering the limited data available, the risk associated with the development of IAS following ALA consumption cannot be quantified precisely. An ALA dose below which IAS is not expected to occur is likely to vary between individuals and cannot be determined from the available data.
Identifiants
pubmed: 34122657
doi: 10.2903/j.efsa.2021.6577
pii: EFS26577
pmc: PMC8173454
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e06577Informations de copyright
© 2021 European Food Safety Authority. EFSA Journal published by John Wiley and Sons Ltd on behalf of European Food Safety Authority.
Références
EFSA J. 2018 Jan 24;16(1):e05123
pubmed: 32625671
Diabetes Metab Syndr Obes. 2020 Apr 01;13:963-978
pubmed: 32308449
Nutrition. 2019 Jan;57:1-4
pubmed: 30086435
Endocrinol Diabetes Metab Case Rep. 2018 Dec 11;2018:
pubmed: 30532997
Clin Chim Acta. 2014 Jun 10;433:135-8
pubmed: 24642342
Diabetes Care. 2007 Sep;30(9):2240-1
pubmed: 17586737
Clin Ther. 2018 Oct;40(10):1720-1728.e2
pubmed: 30241687
J Clin Endocrinol Metab. 1998 Feb;83(2):643-8
pubmed: 9467587
Eur J Clin Pharmacol. 1996;50(6):513-4
pubmed: 8858282
Nucleic Acids Res. 2020 Jan 8;48(D1):D783-D788
pubmed: 31722398
Diabetes Care. 2007 Dec;30(12):e131
pubmed: 18042740
J Immunol. 1993 Nov 15;151(10):5770-6
pubmed: 8228261
Diabetes Res Clin Pract. 2007 Mar;75(3):366-7
pubmed: 16963149
Intern Med. 2007;46(5):237-9
pubmed: 17329919
EFSA J. 2021 Jun 03;19(6):e06577
pubmed: 34122657
Hum Immunol. 2000 Feb;61(2):154-7
pubmed: 10717808
Acta Biomed. 2014 Aug 20;85(2):108-15
pubmed: 25245645
Minerva Med. 2011 Dec;102(6):475-82
pubmed: 22193379
Endokrynol Pol. 2020;71(2):204-205
pubmed: 31909453
Regul Toxicol Pharmacol. 2006 Oct;46(1):29-41
pubmed: 16904799
Regul Toxicol Pharmacol. 2006 Dec;46(3):193-201
pubmed: 16899332
J Endocrinol Invest. 2017 Jan;40(1):9-20
pubmed: 27624297
Clin Endocrinol (Oxf). 2014 Aug;81(2):204-9
pubmed: 24111525
Clin Endocrinol (Oxf). 2020 May;92(5):409-420
pubmed: 32064669
Endocr Pract. 2002 Jan-Feb;8(1):29-35
pubmed: 11951812
Med Clin (Barc). 2015 Jan 20;144(2):93-4
pubmed: 24703419
Int J Mol Sci. 2016 Jun 15;17(6):
pubmed: 27314343
Endocrinol Metab (Seoul). 2013 Dec;28(4):326-30
pubmed: 24396698
J Clin Endocrinol Metab. 1988 Jan;66(1):153-8
pubmed: 3275683
J Clin Pharmacol. 2003 Nov;43(11):1257-67
pubmed: 14551180
SAGE Open Med Case Rep. 2018 Dec 26;6:2050313X18819601
pubmed: 30627435
Endocrinol Diabetes Metab Case Rep. 2018 Dec 11;2018:
pubmed: 30532998
Eur J Pharm Sci. 1999 Apr;8(1):57-65
pubmed: 10072479
Pharmacol Rep. 2005 Sep-Oct;57(5):570-7
pubmed: 16227639
Biomed Pharmacother. 1989;43(8):581-6
pubmed: 2698754
Diabetes Res Clin Pract. 1990 Nov-Dec;10(3):211-4
pubmed: 2073867
Endocrine. 2020 Mar;67(3):729-732
pubmed: 31734778
Gen Pharmacol. 1997 Sep;29(3):315-31
pubmed: 9378235
Clin Chem Lab Med. 2018 May 24;56(6):889-895
pubmed: 28917079
Clin Nutr. 2021 Mar;40(3):1176-1185
pubmed: 32778460
Int J Clin Pharmacol Ther. 1998 Dec;36(12):625-8
pubmed: 9876998
J Chromatogr A. 2000 Feb 18;870(1-2):381-8
pubmed: 10722093
Clin Chem Lab Med. 2016 Nov 1;54(11):1715-1724
pubmed: 27071154
Endocrinol Metab Clin North Am. 1999 Sep;28(3):603-18, vii
pubmed: 10500933
J Chromatogr B Analyt Technol Biomed Life Sci. 2011 Jun 15;879(20):1725-31
pubmed: 21550862
Clin Exp Hypertens. 2007 Nov;29(8):575-86
pubmed: 18058482
J Diabetes Investig. 2020 May;11(3):554-563
pubmed: 31742894
Diabetes Care. 2011 Sep;34(9):e146
pubmed: 21868770
Methods Mol Biol. 2015;1208:345-60
pubmed: 25323519
Clin Diabetes. 2016 Jul;34(3):164-7
pubmed: 27621535
Int J Clin Pharmacol Ther. 2014 Dec;52(12):1083-92
pubmed: 25345429
Free Radic Biol Med. 1998 Apr;24(6):1023-39
pubmed: 9607614
Ann Transl Med. 2018 Sep;6(17):335
pubmed: 30306074
Clin Pharmacol. 2014 Nov 28;6:195-204
pubmed: 25506250
Endocrinol Diabetes Metab Case Rep. 2020 Jun 04;2020:
pubmed: 32554828
Int J Clin Pharmacol Ther Toxicol. 1992 Nov;30(11):511-2
pubmed: 1490813
Diabetologia. 1990 Dec;33(12):719-25
pubmed: 2127403